While epigenetic processes have been linked to aging and disease in other systems, it is not yet known whether they relate to reproductive aging. Recently, we developed a highly accurate epigenetic biomarker of age (known as epigenetic clock) which is based on DNA methylation levels. Here we carry out an epigenetic clock analysis of blood, saliva, and buccal epithelium using data from four large studies: Women's Health Initiative (n=1,864), InCHIANTI (n=200), PEG (n=256), and the United Kingdom Medical Research Council National Survey of Health and Development (NSHD) (n=790). We find that increased epigenetic age acceleration in blood is significantly associated with earlier menopause (P=0.00091), bilateral oophorectomy (P=0.0034), and a longer time since menopause (P=0.017). Conversely, buccal epithelium and saliva do not relate to age at menopause, however lower epigenetic age is exhibited in women who undergo menopausal hormone therapy (P=0.00078). Using genetic data we find evidence of co-heritability between age at menopause and epigenetic age acceleration in blood. Using Mendelian randomization analysis we find that two SNPs that are highly associated with age at menopause exhibit a significant association with epigenetic age acceleration. Overall, our Mendelian randomization approach and other lines of evidence suggest that menopause accelerates epigenetic aging of blood, but mechanistic studies will be needed to further dissect cause-and-effect relationships.
Abstract
While epigenetic processes have been linked to aging and disease in other systems, it is not yet known whether they relate to reproductive aging. Recently, we developed a highly accurate epigenetic biomarker of age (known as epigenetic clock) which is based on DNA methylation levels. Here we carry out an epigenetic clock analysis of blood, saliva, and buccal epithelium using data from four large studies: Women's Health Initiative (n=1,864), InCHIANTI (n=200), PEG (n=256), and the United Kingdom Medical Research Council National Survey of Health and Development (NSHD) (n=790). We find that increased epigenetic age acceleration in blood is significantly associated with earlier menopause (P=0.00091), bilateral oophorectomy (P=0.0034), and a longer time since menopause (P=0.017). Conversely, buccal epithelium and saliva do not relate to age at menopause, however lower epigenetic age is exhibited in women who undergo menopausal hormone therapy (P=0.00078). Using genetic data we find evidence of co-heritability between age at menopause and epigenetic age acceleration in blood. Using Mendelian randomization analysis we find that two SNPs that are highly associated with age at menopause exhibit a significant association with epigenetic age acceleration. Overall, our Mendelian randomization approach and other lines of evidence suggest that menopause accelerates epigenetic aging of blood, but mechanistic studies will be needed to further dissect cause-and-effect relationships.
Significance Statement
Within an evolutionary framework, aging and reproduction are intrinsically linked. While both laboratory and epidemiological studies have observed associations between the timing of reproductive senescence and longevity, it is not yet known whether differences in the age of menopause are reflected in biomarkers of aging. Using our recently developed biomarker of aging,
INTRODUCTION
Reproductive senescence, concluding in menopause, is a feature of all female mammals(1), yet humans are unique in that they experience exceptionally long post-reproductive lifespans.
Within human populations, the timing of menopause onset has been linked to susceptibility for age-related morbidity and mortality outcomes (1) . For instance, observational studies have uncovered associations between a woman's age at menopause and her subsequent risk of mortality.
Results based on 12,134 Dutch women showed that for every one year increase in the age of menopause, age-adjusted mortality rate was decreased by 2% (2) .
While social/behavioral and developmental factors, such as smoking, lifetime socioeconomic circumstances , infant growth, breastfeeding, and childhood cognitive ability have been shown to influence reproductive aging, age at menopause is also considered to be highly heritable, with estimates from twin and sibling studies ranging from about 0.40-0.70 (3) (4) (5) (6) (7) (8) (9) (10) . A recent large-scale genome-wide association study identified 44 genomic loci with common variants that significantly related to age at menopause (11) , while a case-control study comparing centenarian women to those with average lifespans, found that individuals from families with a history of longevity also tend to exhibit delayed reproductive aging (12) .
While these and other studies suggest that there might be a relationship between age at menopause and the biological aging rate, it has been difficult to test this hypothesis due to the dearth of molecular biomarkers of aging. Several recent articles describe epigenetic biomarkers of aging based on methylation levels (13) (14) (15) (16) , drawing upon the fact that chronological age has a profound effect on DNA methylation (DNAm) levels (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) . While previous articles describe epigenetic age measures that only apply to a single tissue (saliva (13 ) or blood (14)), our recently developed "epigenetic clock" method (based on 353 CpGs) applies to every human tissue and cell type that contain DNA, with the exception of sperm (15) . Age acceleration effects can be estimated by contrasting DNAm age with an individual's chronological age. For instance, a woman whose blood has a higher DNAm age than expected based upon her chronological age, can be said to exhibit positive age acceleration-or can be thought of as aging faster than expected. Age acceleration has also been shown to have a strong genetic basis-with heritability estimates of 40% for older subjects (15, 27) . While the epigenetic clock has been shown to relate to a number of aging-related outcomes (27) (28) (29) (30) , it is not yet known whether it relates to reproductive aging.
Using data from four large observational studies-Women's Health Initiative (WHI), InCHIANTI, PEG, and NSHD-we examine the association between epigenetic age and: age at menopause, bilateral oophorectomy, and the use of menopausal hormone therapies (MHT). Given the strong heritability of both age at menopause and epigenetic age, we also estimate the genetic correlation between age at menopause and epigenetic aging, and carry out a Mendelian randomization analysis, to examine causality, using the top two SNPs shown previously to be strongly associated with age at menopause (31) .
RESULTS

Age acceleration of blood versus age at menopause
In our primary analysis, we consider only women whose menopause occurred after age 30.
As shown in Table 1 , based on result from Pearson correlations in each of our three blood datasets (WHI, InCHIANTI, and PEG), meta-analysis showed that age at menopause was significantly associated with epigenetic age acceleration (p=0.00091). Similar meta-analytic p-values were obtained in our secondary analysis, which excluded women with surgical menopause (p=0.0083), and in our tertiary analysis, which used all women regardless of age or type (natural/surgical) of menopause (p=0.0061). Pearson correlation results from individual studies and stratifying by race/ethnicity can be found in Figure S1 .
Multivariate linear models linking age acceleration with age at menopause
Using blood methylation data from WHI, InCHIANTI, and PEG we conducted multivariate regression for women who experienced menopause after age 30, and combined results using metaanalysis to determine whether covariates accounted for the association between epigenetic age acceleration and age at menopause ( Table 2 ). Models were adjusted for age, race/ethnicity (in WHI and PEG), smoking status, age at menarche, and MHT use. Additionally, models run using PEG data, were also adjusted for Parkinson's disease (PD). In order to retain the moderate number of women with missing data on MHT use in PEG, those who were missing were coded as "never", and a dummy variable for missing was added to the model. After adjusting for possible confounders we find that higher epigenetic age acceleration is associated with a younger age at menopause (Meta-p=8.32×10 -4 ).
Time since Menopause
To examine whether menopause may be contributing to accelerated aging, we tested the association between epigenetic aging and time since menopause, using multivariate models that adjust for race/ethnicity (WHI and PEG), and smoking (Table S2) . Results showed that the variable "time since menopause" was associated with AgeAccel (=0.038, P=0.007) in the WHI and in our meta-analysis (AgeAccel P=0.017).
Surgical menopause is associated with epigenetic age acceleration
The menopause of a substantial number of women was due to bilateral oophorectomy (i.e.
n=127 women in WHI-white, 112 in WHI-black, 50 women in WHI-Hispanic, and 48 women in PEG). We evaluated the effect of surgical menopause on epigenetic age acceleration among women whose bilateral oophorectomy took place before age 50 (Figure 1) . The association was highly consistent across the blood data sets (Figure 1 ) which led to a significant meta-analysis Pvalue for all 3 measures of age acceleration: AgeAccel (Stouffer's Z=3.2. p=0.0014).
Genetic correlation and Mendelian randomization between epigenetic age acceleration and age at menopause
Using the WHI data (n=1,940), we conducted a bivariate REML analysis to examine the overlap in genetic variants that accounted for the heritability of both age at menopause and epigenetic age acceleration. As shown in Table 3 , the 10,769,392 autosomal SNPs or INDEL markers included in the analysis accounted for about 38% of the variance in age at menopause and 65% of the variance in AgeAccel. The genetic correlation (or pleiotropy) between AgeAccel and age of menopause was marginally significant with rG=-0.256 (one-sided P=0.054).
Although we clearly demonstrate that age at menopause relates to epigenetic age acceleration, our cross sectional data make it difficult to dissect causal relationships. Mendelian randomization (reviewed in (32))-the random assortment of genes from parents to offspring that occurs during gamete formation and conception-provides one method for assessing the causal nature of associations. Here we test the hypothesis that menopause leads to an acceleration of epigenetic aging by leveraging the two most highly significant SNPs from a genome-wide association study for age at menopause (rs11668344 Replication P-value= 2.65×10 −18 , rs16991615
Replication P-value= 7.90×10 −21 ). If menopause accelerates epigenetic aging then one would expect these two SNPs to also relate to epigenetic age acceleration, which is what was found ( Table 4 ) for rs11668344 (P=0.031). Additionally, the directionality of the associations is consistent with the causal model (SNPage at menopauseage acceleration), i.e. the minor allele is associated with earlier age at menopause and higher epigenetic age acceleration. On the other hand, rs16991615 was not associated with epigenetic age acceleration (P=0.763).
Analysis of buccal epithelium and saliva
We are not aware of any biological reason that suggests that blood tissue stands out when it comes to studying menopausal effects. Several previous data sets demonstrate that the epigenetic clock method also applies to buccal epithelium (35) . As a result, we also examined epigenetic age measured in 790 buccal epithelium samples from National Survey of Health and Development (NSHD) from the United Kingdom Medical Research Council.
Unlike results in blood, MHT is associated with a significantly lower epigenetic age acceleration of buccal epithelium (p=0.00078, Figure 2A) ; whereas age at natural or surgical menopause does not correlate with epigenetic age acceleration across the n=419 postmenopausal buccal samples ( Figure 2B and 2D, respectively); and no significant association was found between age acceleration and menopausal status at age 53-n=419 post-versus 371 premenopausal samples ( Figure 2C ).
We also analyzed saliva samples from 113 women from the PEG study of whom 16 had undergone surgical menopause. Similar to buccal epithelium, age at menopause and time since menopause were not associated with epigenetic age acceleration in saliva which might reflect the low sample size. However, surgical menopause was associated with increased AgeAccel of saliva (P=0.0079, Figure 3) .
DISCUSSION
To the best of our knowledge, this is the first study that shows a) that the epigenetic age of blood has a negative correlation with age at menopause, b) that surgical menopause is associated with an increased epigenetic age of blood and saliva, c) that menopausal hormone therapy is inversely associated with epigenetic age acceleration of buccal epithelium, and d) that a SNP which relate to age at menopause also relates to epigenetic age acceleration. While our study demonstrates that postmenopausal women with a late onset of menopause are epigenetically younger than women with an early onset of menopause, it is challenging to dissect cause and effect relationships. In the following, we discuss several causal scenarios that could explain the reported findings (Fig. S2) .
The first causal model (age at menopause  Biological Age  Epigenetic age acceleration) assumes that both "age at menopause" and "epigenetic age acceleration" are indicator variables of a latent variable, which can be thought of as true biological age. There is evidence that risk factors for heart disease, which arguably accelerate biological age, are likely to contribute to an earlier age of menopause, rather than the commonly held notion that early menopause is a risk factor for heart disease(33). Consistent with evolutionary theories of aging, genetic predisposition to later menopause may coincide with an innate protection against early mortality (34) . In this study, we observe a suggestive genetic correlation between age at menopause and epigenetic age acceleration, which may suggest that increased age at menopause is genetically linked to decreased epigenetic age acceleration. This advocates for a common genetic etiology and is consistent with both variables being indirect measures of biological age-genetic variants which influence biological aging may therefore lead to both slower reproductive aging and lower epigenetic age.
Another causal model assumes that menopause leads to an increase of epigenetic age. This model is supported by the following lines of evidence. First, we find that longer time since menopause (irrespective of age at menopause) is associated with increased epigenetic age acceleration. Second, bilateral oophorectomy is associated with increased epigenetic age acceleration in both blood and saliva. This finding is congruent with a growing body of evidence suggesting that the premature loss of ovarian function caused by bilateral oophorectomy performed before natural menopause contributes to increased susceptibility to premature death, cardiovascular disease, dementia, parkinsonism, osteoporosis and bone fractures (35) . This is also consistent with findings showing that transplantation of young ovaries in old mice significantly increases lifespan (36) . Third, our study demonstrated that MHT, which arguably counters some of the effects of menopause, is associated with a decreased epigenetic age acceleration of buccal epithelium (but not of blood). Fourth, our Mendelian randomization analysis provided evidence of a causal pathway in which menopause accelerates epigenetic aging in blood-one of the most significant SNPs (rs11668344) for age of menopause also relates to epigenetic age acceleration in blood. Although we acknowledge that each of the above mentioned arguments in support of the causal model has pitfalls, in aggregate our results strongly support the causal model: Menopause  Epigenetic age acceleration.
In moving forward, it will be important to examine longitudinal change in epigenetic age of blood before and after women transition from pre-to post-menopausal status. Additionally, it will be important to examine how long it takes accelerated epigenetic aging effects to become apparent following surgical menopause or whether they were apparent before. For instance, if accelerated aging is triggered by menopause, then one would expect age acceleration to increase as a function of time since bilateral oophorectomy. However, if the condition that led to a surgical removal of both ovaries (e.g. fibroids, menstrual disorders, endometriosis) is driving age acceleration, one would not see a linear increase in epigenetic age acceleration over time. The reason for bilateral oophorectomy was available from the NSHD sample. Overall, most women underwent bilateral oophorectomy due to reported fibroids, menstrual disorders, endometriosis (or some combination of these) in both groups (Table S3) . Similar prevalence estimates apply to the blood data from PEG.
While our study detected an association between epigenetic age in blood and age at menopause, similar associations were not found for epigenetic age estimates from buccal epithelium. One potential explanation is that aging measures in the various tissues are capturing different phenomena. While we find a robust correlation between AgeAccel in blood and saliva (r=0.70) (Figure S2) , when comparing the measures of AgeAccel in women with data from both blood and buccal epithelium, we find that the correlation is relatively weak (r=0.20) (Figure S3 ).
At first sight, the low correlation of age acceleration between tissues is surprising. However, we interpret it as follows. The epigenetic clock is a strong predictor of age in multiple tissue when comparing across individuals. However, that does not mean that it will be correlated across tissues when comparing within-person differences. Stress factors and other perturbations act largely in a tissue specific manner (37) . For that reason, one may not expect all tissue within an individual to age at the same rate, thus potentially accounting for the low/moderate correlation between epigenetic age acceleration in blood and buccal epithelium.
To the best of our knowledge, our study is the first to demonstrate that reproductive age, bilateral oophorectomy, and MHT relate to measures of epigenetic age acceleration-but the reported associations are specific to either blood, buccal epithelium, or saliva. Future studies are warranted for examining these effects in other tissues. Since epigenetic age captures aspects of biological age (27) (28) (29) (30) , our study strongly suggests that the hormonal changes that accompany menopause accelerate biological aging in women.
METHODS
Data set 1: WHI Sample Description (blood)
Participants were part of a subsample from the Women's Health Initiative (WHI), who were enrolled in an integrative genomics study with a primary aim of identifying novel genomic determinants of CHD. This sample included women ages 50-79, with an overrepresentation of racial/ethnic minorities. The WHI is a national study that began in 1993 which enrolled postmenopausal women. Women who were ineligible to participate in the trials or who chose not to be randomized were invited to participate in the observational arm of the study. The integrative genomics subsample employed a case-control sampling design. All cases and controls were required to have already undergone genome wide genotyping at baseline as well as profiling of seven cardiovascular biomarkers, as dictated by the aims of other ancillary WHI studies. reported they were current smokers at the time of blood draw.
As shown in
At baseline, the majority of women did not have a history of any MHT use (61.1%), while approximately 21% were past users and 18% were current users. Of those who had a history of MHT, 17% were past users of unopposed estrogen, 12% were current users of unopposed estrogen, 6% were past users of estrogen plus progestin, and 5.5% were current users of estrogen plus progestin. Additionally, the majority of users were on MHT for less than five years (55%), while 16.7% took MHT for 5-9 years, about 10% took MHT for 10-14 years, and 18% took MHT for 15 or more years.
Data set 2: InCHIANTI Sample Description (blood)
The Invecchiare nel Chianti (InCHIANTI) Study is a population-based prospective cohort study of residents ages 30 or older from two areas in the Chianti region of Tuscany, Italy. Sampling and data collection procedures have been described elsewhere (38) . Briefly, participants were enrolled between 1998-2000 and were examined at three-year intervals. Overall 1,326 participants donated a blood sample at baseline (1998) (1999) (2000) , of which 784 also donated a blood sample at the
9-year follow-up (2007-2009). DNA methylation was assayed using the Illumina Infinium
HumanMethylation450 platform for participants with sufficient DNA at both baseline and Year 9 visits (n=499). Our study focused only on women (n=200). Ages for the 200 women in InCHIANTI ranged from 50 to 91, with a mean age of 70.64 years (Table S1 ), whereas baseline 
Data set 3: Women from the PEG cohort (blood and saliva)
We used two types of tissues from the Parkinson's disease, Environment, and Genes (PEG) study cohort: blood and saliva. The PEG study is a large population-based case-control study of
Parkinson's disease of rural and township residents of California's central valley (39) . Our blood data come from subjects from wave 1 (PEG1). Parkinson's disease status did not confound the relationship in blood because it was not associated with age at menopause, however we adjusted for it in multivariate analyses. The 256 women in PEG ranged in age from 35 to 91 years, with a mean age of 67.9 years (Table S1) The saliva methylation data were collected at a later time point than the blood data. For about half of the women, we had both blood and saliva methylation data but epigenetic age acceleration of blood tissue was not correlated with age acceleration in saliva.
Data set 4. NSHD (buccal epithelium)
These buccal samples stem from a subsample of 790 women participants in a British birth cohort, the United Kingdom Medical Research Council National Survey of Health and Development (NSHD) as described in (40) . The women were all aged 53 years at the time of sample collection in 1999. At that time, 419 women were post-menopausal and 371 women were pre-menopausal. MHT status was coded as "yes" only if MHT started before the age of sample collection (i.e. 53). Our results regarding the relationship between "age at menopause" and epigenetic age acceleration were largely unchanged after excluding women who experienced surgical menopause.
All women gave written informed consent for their samples to be used in genetic studies of health, and the Central Manchester Research Ethics Committee approved the use of these samples for epigenetic studies of health in 2012. Women were selected from those who provided a buccal and blood sample at age 53 years in 1999, who had not previously developed any cancer, and who had complete information on epidemiological variables of interest. Smoking status did not confound the reported relationships because smoking was not significantly associated with our measure of epigenetic age acceleration.
DNA methylation data
All DNA methylation data sets used the Illumina Infinium 450K platform. The Illumina
BeadChips measures bisulfite-conversion-based, single-CpG resolution DNA methylation levels at 485577 different CpG sites in the human genome. These data were generated by following the standard protocol of Illumina methylation assays, which quantifies methylation levels by the β value using the ratio of intensities between methylated and un-methylated alleles. Specifically, the β value is calculated from the intensity of the methylated (M corresponding to signal A) and un- to 1 (completely methylated). For our blood data sets (WHI, PEG) we used background corrected beta values. Consistent with the original publication, buccal samples were normalized using the BMIQ method (41) . The correlation between DNAm age and chronological age is highly robust with respect to different normalization methods because a) the epigenetic clock implements a custom normalization methods and b) it was constructed using training data that were normalized in different ways.
Epigenetic age acceleration
We used the DNAm age based biomarker of aging from (15) because a) its accurate measurement of age across tissues is unprecedented (and it applies to both blood and buccal epithelium), b) it is prognostic for all-cause mortality (27, 28) , c) it correlates with measures of cognitive and physical fitness in the elderly (27, 42) , and d) it has been found useful for studying aging effects in Down syndrome(43), Parkinson's disease (44) , neuropathological variables (42); obesity (37) , and HIV infection (45) . DNAm age was defined using the 353 CpGs and coefficient values reported in (15) .
These CpGs and coefficient values were chosen in independent data using the elastic net penalized regression model to regress age on CpGs, resulting in a DNAm age measures defined as predicted age, in years.
Our measure of age acceleration (AgeAccel), which applies to all sources of DNA, was defined as residual resulting from a linear model that regressed DNAm age on chronological age.. Thus, a positive value for AgeAccel indicates that the observed DNAm age is higher than expected.
AgeAccel has only a weak correlation with blood cell counts (45) .
Genome-wide SNP data from the WHI
Genotyping was performed for all participants on Affymetrix 6.0, Illumina HumanOmni1-Quad v1.0, or Illumina HumanOmniExpressExome-8v1.0. Imputation was performed using
MaCH with haplotypes phased in Beagle or Minimac (46, 47 Finally, to account for population structure, principal component analysis (PCA) was performed to generate sample eigenvectors, the first two of which were included as covariates in all GCTA analysis.
We related the two highly significant SNPs from the recent large-scale meta-analysis of age at menopause(31) to age acceleration using the WHI data. Association analysis was conducted in the two subsets of individuals stratified by platform. All women were of European ancestry, identified by multidimensional scaling analysis in PLINK. We combined the results into a single estimate by fixed-effects models weighted by inverse variance, as implemented in R metafor. For association analysis, we regressed each of the three age acceleration trait values on expected genotype dosage, adjusted for the first two principal components when necessary.
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Availability of data
The WHI and inCHIANTI data are available through NHLBI There is a strong correlation between epigenetic age (y-axis) and chronological age (A). While the correlation between epigenetic age acceleration and age at menopause in saliva (B) is about twice that of the association in blood, the finding is not significant. However, we do observe an association between epigenetic age acceleration and (C) surgical menopause (P=0.0079). We did not adjust for race/ethnicity in the models run for InCHIANTI, given that all participants are non-Hispanic white. For all models, women with age at menopause <30 years were excluded. 
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